Literature DB >> 15542819

Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment.

M Breccia, M Muscaritoli, Z Aversa, F Mandelli, G Alimena.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15542819     DOI： 10.1200/JCO.2004.04.217

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  31 in total

1.  Identifying mechanism-of-action targets for drugs and probes.

Authors:  Elisabet Gregori-Puigjané; Vincent Setola; Jérôme Hert; Brenda A Crews; John J Irwin; Eugen Lounkine; Lawrence Marnett; Bryan L Roth; Brian K Shoichet
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-18       Impact factor: 11.205

2.  Loss of PDGF-B activity increases hepatic vascular permeability and enhances insulin sensitivity.

Authors:  Summer M Raines; Oliver C Richards; Lindsay R Schneider; Kathryn L Schueler; Mary E Rabaglia; Angie T Oler; Donald S Stapleton; Guillem Genové; John A Dawson; Christer Betsholtz; Alan D Attie
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-06-14       Impact factor: 4.310

Review 3.  Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.

Authors:  Rongras Damrongwatanasuk; Michael G Fradley
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-04

Review 4.  Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.

Authors:  Peter Valent; Emir Hadzijusufovic; Gregor Hoermann; Wolfgang Füreder; Gerit-Holger Schernthaner; Wolfgang R Sperr; Rudolf Kirchmair; Dominik Wolf
Journal:  Leuk Res       Date:  2017-05-12       Impact factor: 3.156

Review 5.  Clinical review: kinase inhibitors: adverse effects related to the endocrine system.

Authors:  Maya B Lodish
Journal:  J Clin Endocrinol Metab       Date:  2013-02-28       Impact factor: 5.958

6.  PPARγ Antagonist Gleevec Improves Insulin Sensitivity and Promotes the Browning of White Adipose Tissue.

Authors:  Sun-Sil Choi; Eun-Sun Kim; Ji-Eun Jung; David P Marciano; Ala Jo; Ja Young Koo; Soo Youn Choi; Yong Ryoul Yang; Hyun-Jun Jang; Eung-Kyun Kim; Jiyoung Park; Hyug Moo Kwon; In Hee Lee; Seung Bum Park; Kyung-Jae Myung; Pann-Ghill Suh; Patrick R Griffin; Jang Hyun Choi
Journal:  Diabetes       Date:  2016-01-06       Impact factor: 9.461

7.  Symptomatic hypoglycemia during imatinib mesylate in a non-diabetic female patient with gastrointestinal stromal tumor.

Authors:  M Haap; B Gallwitz; C Thamer; K Müssig; H-U Häring; L Kanz; J T Hartmann
Journal:  J Endocrinol Invest       Date:  2007-09       Impact factor: 4.256

8.  Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5'-phosphatase interaction with c-Abl.

Authors:  D Mokhtari; A Al-Amin; K Turpaev; T Li; O Idevall-Hagren; J Li; A Wuttke; R G Fred; P Ravassard; R Scharfmann; A Tengholm; N Welsh
Journal:  Diabetologia       Date:  2013-03-05       Impact factor: 10.122

9.  Imatinib induces apoptosis by inhibiting PDGF- but not insulin-induced PI 3-kinase/Akt survival signaling in RGC-5 retinal ganglion cells.

Authors:  Swarajit K Biswas; Yan Zhao; Lakshman Sandirasegarane
Journal:  Mol Vis       Date:  2009-08-15       Impact factor: 2.367

10.  EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice.

Authors:  Patricia O Prada; Eduardo R Ropelle; Rosa H Mourão; Claudio T de Souza; Jose R Pauli; Dennys E Cintra; André Schenka; Silvana A Rocco; Roberto Rittner; Kleber G Franchini; José Vassallo; Lício A Velloso; José B Carvalheira; Mario J A Saad
Journal:  Diabetes       Date:  2009-08-20       Impact factor: 9.461
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.